CN110022935A - 用于心血管病况的德谷胰岛素 - Google Patents

用于心血管病况的德谷胰岛素 Download PDF

Info

Publication number
CN110022935A
CN110022935A CN201780073496.7A CN201780073496A CN110022935A CN 110022935 A CN110022935 A CN 110022935A CN 201780073496 A CN201780073496 A CN 201780073496A CN 110022935 A CN110022935 A CN 110022935A
Authority
CN
China
Prior art keywords
subject
insulin
disease
mace
insulin degludec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780073496.7A
Other languages
English (en)
Chinese (zh)
Inventor
S.斯基斯特
K.科维斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN110022935A publication Critical patent/CN110022935A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780073496.7A 2016-11-28 2017-11-28 用于心血管病况的德谷胰岛素 Pending CN110022935A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16200906.2 2016-11-28
EP16200906 2016-11-28
EP17174682 2017-06-07
EP17174682.9 2017-06-07
PCT/EP2017/080600 WO2018096162A1 (en) 2016-11-28 2017-11-28 Insulin degludec in cardiovascular conditions

Publications (1)

Publication Number Publication Date
CN110022935A true CN110022935A (zh) 2019-07-16

Family

ID=60937677

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780073496.7A Pending CN110022935A (zh) 2016-11-28 2017-11-28 用于心血管病况的德谷胰岛素

Country Status (6)

Country Link
US (2) US11278596B2 (https=)
EP (1) EP3544683A1 (https=)
JP (1) JP7193455B2 (https=)
CN (1) CN110022935A (https=)
MA (1) MA46897A (https=)
WO (1) WO2018096162A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018096162A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
AR112015A1 (es) 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
CN113773397B (zh) * 2020-06-10 2023-10-20 宁波鲲鹏生物科技有限公司 一种德谷胰岛素的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014177623A1 (en) * 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
CN104334183A (zh) * 2012-03-28 2015-02-04 赛诺菲 基底胰岛素治疗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
GB0309154D0 (en) * 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
MXPA06001283A (es) 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
JP6755175B2 (ja) * 2013-03-20 2020-09-16 ノヴォ ノルディスク アー／エス インスリン投薬レジメン
MA46890A (fr) 2016-11-28 2021-04-28 Novo Nordisk As Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme
WO2018096162A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec in cardiovascular conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104334183A (zh) * 2012-03-28 2015-02-04 赛诺菲 基底胰岛素治疗
WO2014177623A1 (en) * 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IRENE M STRATTON等: "Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study", 《BMJ》 *
YOSHIO NAGAI等: "Efficacy and safety of thrice-weekly insulin degludec in elderly patients with type 2 diabetes assessed by continuous glucose monitoring", 《ENDOCRINE JOURNAL》 *

Also Published As

Publication number Publication date
MA46897A (fr) 2021-04-28
WO2018096162A1 (en) 2018-05-31
EP3544683A1 (en) 2019-10-02
JP7193455B2 (ja) 2022-12-20
JP2019535785A (ja) 2019-12-12
US11278596B2 (en) 2022-03-22
US20220160840A1 (en) 2022-05-26
US20190374614A1 (en) 2019-12-12
US12233114B2 (en) 2025-02-25

Similar Documents

Publication Publication Date Title
US12233114B2 (en) Method for treating diabetes
US20250288649A1 (en) Semaglutide in Cardiovascular Conditions
AU2024201937A1 (en) Liraglutide in cardiovascular conditions
US11673933B2 (en) Method for using insulin degludec for the improvement of glycemic control and reduction of acute and long-term diabetes complications
WO2018096164A1 (en) Insulin degludec for treating diabetes
CN108883158A (zh) 用于肾脏病况的利拉鲁肽
CN108883159A (zh) 用于糖尿病性足溃疡的利拉鲁肽
HK1259166B (en) Liraglutide in cardiovascular conditions
HK1259166A1 (en) Liraglutide in cardiovascular conditions
BR122025010585A2 (pt) Uso de semaglutida para reduzir o risco de um evento cardiovascular adverso maior (mace) em indivíduos com diabetes mellitus tipo 2 e alto risco cardiovascular

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190716

RJ01 Rejection of invention patent application after publication